Revelation Biosciences In... (REVBW)
NASDAQ: REVBW
· Real-Time Price · USD
0.01
-0.00 (-10.71%)
At close: Jun 09, 2025, 2:31 PM
Revelation Biosciences Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -2.09M | -1.75M | -1.8M | -2.52M | -1.9M | -2.33M | -2.78M | -1.93M | -1.62M | -1.22M | -1.2M | -1.86M | -6.59M | -3.86M | -3.04M | -2.44M | -2.61M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 28.73K | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -2.05M | -1.73M | -2.24M | -8.39M | -2.68M | -2.2M | -2.63M | -1.45M | 6.16M | -1.21M | -1.17M | -1.83M | -6.62M | -3.86M | -3.04M | -2.47M | -2.61M |
Net Income | -2.05M | -1.73M | -2.24M | -8.39M | -2.68M | -2.2M | -2.63M | -1.45M | 6.16M | -1.21M | -1.17M | -1.83M | -6.62M | -3.86M | -3.04M | -2.47M | -2.61M |
Selling & General & Admin | 1.24M | 1.15M | 965.71K | 1.13M | 1.18M | 1.27M | 1.13M | 1.02M | 1.09M | 878.36K | 817.9K | 884.84K | 2.91M | 1.19M | 1.51M | 1.28M | 1.05M |
Research & Development | 858.83K | 605.5K | 830.98K | 1.39M | 717.58K | 1.06M | 1.65M | 909.28K | 525.27K | 339.97K | 381.57K | 975.58K | 3.68M | 2.67M | 1.53M | 1.16M | 1.56M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 2.09M | 1.75M | 1.8M | 2.52M | 1.9M | 2.33M | 2.78M | 1.93M | 1.62M | 1.22M | 1.2M | 1.86M | 6.59M | 3.86M | 3.04M | 2.44M | 2.61M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 557.00 | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 2.09M | 1.75M | 1.8M | 2.52M | 1.9M | 2.33M | 2.78M | 1.93M | 1.62M | 1.22M | 1.2M | 1.86M | 6.59M | 3.86M | 3.04M | 2.44M | 2.61M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 971.31K | 346.5K | 2.68M | 1.64M | 1.09M | 264.54K | 209.91K | 193.74K | 73.69K | 22.76K | 20.05K | 14.36K | 13.53K | 7.94K | 8.66K | 8.66K | 8.66K |
Shares Outstanding (Diluted) | 971.31K | 346.5K | 2.68M | 1.64M | 1.09M | 264.54K | 209.91K | 193.74K | 104.53K | 22.76K | 20.05K | 14.36K | 13.53K | 7.94K | 8.66K | 8.66K | 8.66K |
EPS (Basic) | -2.11 | -1.01 | -0.84 | -5.13 | -2.46 | -8.33 | -12.52 | -7.47 | 189.15 | -52.78 | -56.95 | -125.94 | -491.44 | -486.32 | -351.38 | -285.03 | -301.52 |
EPS (Diluted) | -2.11 | -1.01 | -0.84 | -5.13 | -2.46 | -8.33 | -12.52 | -7.47 | 133.34 | -52.78 | -56.95 | -125.94 | -491.44 | -486.32 | -351.38 | -285.03 | -301.52 |
EBITDA | -2.09M | -1.75M | -1.79M | -2.52M | -1.9M | -2.32M | -2.77M | -1.93M | -1.61M | -1.21M | -1.19M | -1.85M | -6.58M | -3.85M | -3.04M | -2.44M | -2.61M |
EBIT | -2.09M | -1.75M | -1.8M | -2.52M | -1.9M | -2.33M | -2.78M | -1.93M | -1.62M | -1.22M | -1.2M | -1.86M | -6.59M | -3.86M | -3.04M | -2.44M | -2.61M |
Depreciation & Amortization | 7.22K | 7.22K | 7.22K | 7.22K | 6.26K | 6.26K | 6.26K | 6.26K | 6.26K | 6.26K | 6.26K | 6.26K | 6.26K | 6.26K | 6.07K | 3.81K | 642.00 |